C3 glomerulopathy: The genetic and clinical findings in dense deposit disease and c3 glomerulonephritis

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 4, 2014, Pages 465-471

  Xiao, Xue ^a   Pickering, Matthew C ^b   Smith, Richard J H ^a  

^a UNIVERSITY OF IOWA   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

C3 glomerulonephritis; C3 glomerulopathy; dense deposit disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; BIOLOGICAL MARKER;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; C3 GLOMERULONEPHRITIS; C3 GLOMERULOPATHY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DENSE DEPOSIT DISEASE; GENETIC SCREENING; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; HAPLOTYPE; HEMOLYTIC UREMIC SYNDROME; HUMAN; INNATE IMMUNITY; KIDNEY FUNCTION; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PLASMAPHERESIS; PRIORITY JOURNAL; ALLELE; COMPLEMENT ALTERNATIVE PATHWAY; GENETIC VARIABILITY; GENETICS; GLOMERULUS; IMMUNOLOGY; KIDNEY DISEASE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; METABOLISM; PATHOLOGY; PHENOTYPE;

ALLELES; BIOLOGICAL MARKERS; COMPLEMENT C3; COMPLEMENT PATHWAY, ALTERNATIVE; GENETIC VARIATION; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNITY, INNATE; KIDNEY DISEASES; KIDNEY GLOMERULUS; PHENOTYPE;

EID: 84902291006     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1376334     Document Type: Article

References (41)

1. Hou J., Markowitz G. S., Bomback A. S., et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int: 2014; 85 2 450 456
2. Sethi S., Fervenza F. C. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost: 2014; 40 4 416 421
3. Servais A., Noël L. H., Frémeaux-Bacchi V., Lesavre P. C3 glomerulopathy. Contrib Nephrol: 2013; 181 185 193
4. Medjeral-Thomas N. R., O'Shaughnessy M. M., O'Regan J. A., et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol: 2014; 9 1 46 53
5. Lu D. F., Moon M., Lanning L. D., McCarthy A. M., Smith R. J. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol: 2012; 27 5 773 781
6. Sethi S., Fervenza F. C., Zhang Y., et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int: 2012; 82 4 465 473
7. Barbour T. D., Pickering M. C., Cook H. T. Recent insights into C3 glomerulopathy. Nephrol Dial Transplant: 2013; 28 7 1685 1693
8. Servais A., Noël L. H., Roumenina L. T., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int: 2012; 82 4 454 464
9. Gale D. P., de Jorge E. G., Cook H. T., et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet: 2010; 376 9743 794 801
10. Athanasiou Y., Voskarides K., Gale D. P., et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol: 2011; 6 6 1436 1446
11. Martínez-Barricarte R., Heurich M., Valdes-Cañedo F., et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest: 2010; 120 10 3702 3712
12. Sethi S., Gamez J. D., Vrana J. A., et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int: 2009; 75 9 952 960
13. Sethi S., Fervenza F. C., Zhang Y., et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol: 2011; 6 5 1009 1017
14. Mayilyan K. R. Complement genetics, deficiencies, and disease associations. Protein Cell: 2012; 3 7 487 496
15. Smith R. J., Harris C. L., Pickering M. C. Dense deposit disease. Mol Immunol: 2011; 48 14 1604 1610
16. Zipfel P. F., Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol: 2009; 9 10 729 740
17. Malik T. H., Lavin P. J., Goicoechea de Jorge E., et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol: 2012; 23 7 1155 1160
18. Tortajada A., Yébenes H., Abarrategui-Garrido C., et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest: 2013; 123 6 2434 2446
19. Medjeral-Thomas N., Malik T. H., Patel M. P., et al. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int: 2014; 85 4 933 937
20. Chen Q., Wiesener M., Eberhardt H., et al. A novel hybrid CFHR2/CFHR5 gene develops MPGN II and provides insights into disease mechanism and therapeutic implications. Immunobiology: 2012; 217 11 1131 1132
21. Goicoechea de Jorge E., Caesar J. J., Malik T. H., et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci USA: 2013; 110 12 4685 4690
22. Skerka C., Chen Q., Fremeaux-Bacchi V., Roumenina L. T. Complement factor H related proteins (CFHRs). Mol Immunol: 2013; 56 3 170 180
23. Boyer O., Noël L. H., Balzamo E., et al. Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. Am J Kidney Dis: 2008; 51 4 671 677
24. Servais A., Noël L. H., Dragon-Durey M. A., et al. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum Pathol: 2011; 42 9 1305 1311
25. Abrera-Abeleda M. A., Nishimura C., Frees K., et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol: 2011; 22 8 1551 1559
26. Westra D., van der Deure J., Volokhina E. B., van den Heuvel L. PWJ, van de Kar N. CAJ. Several genetic aberrations in different complement genes in a patient with dense deposit disease. Mol Immunol: 2011; 48 14 1682
27. Zhang Y., Meyer N. C., Wang K., et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol: 2012; 7 2 265 274
28. de Jorge E. G., Gale D. P., Cook H. T., et al. A mutant complement factor H-related 5 protein is associated with familial C3 glomerulonephritis. Mol Immunol: 2009; 46 14 2822
29. Servais A., Frémeaux-Bacchi V., Lequintrec M., et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet: 2007; 44 3 193 199
30. Human Gene Mutation Database (HGMD). Available at: http://www.hgmd.org/; Accessed December 9, 2013
31. Chen Q., Müller D., Rudolph B., et al. Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med: 2011; 365 24 2340 2342
32. Strobel S., Zimmering M., Papp K., Prechl J., Józsi M. Anti-factor B autoantibody in dense deposit disease. Mol Immunol: 2010; 47 7-8 1476 1483
33. Goodship T. H., Pappworth I. Y., Toth T., et al. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol: 2012; 52 3-4 200 206
34. Pickering M. C., D'Agati V. D., Nester C. M., et al. C3 glomerulopathy: consensus report. Kidney Int: 2013; 84 6 1079 1089
35. Banks R. A., May S., Wallington T. Acute renal failure in dense deposit disease: recovery after plasmapheresis. Br Med J (Clin Res Ed): 1982; 284 6332 1874 1875
36. Krmar R. T., Holtbäck U., Linné T., et al. Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange. Clin Nephrol: 2011; 75 01 4 10
37. McCaughan J. A., O'Rourke D. M., Courtney A. E. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant: 2012; 12 4 1046 1051
38. Gurkan S., Fyfe B., Weiss L., Xiao X., Zhang Y., Smith R. J. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol: 2013; 28 10 1975 1981
39. Riedl M., Fakhouri F., Le Quintrec M., et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost: 2014; 40 4 444 464
40. Herlitz L. C., Bomback A. S., Markowitz G. S., et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol: 2012; 23 7 1229 1237
41. Bomback A. S., Smith R. J., Barile G. R., et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol: 2012; 7 5 748 756